Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GI safety of OTC ibuprofen

This article was originally published in The Tan Sheet

Executive Summary

Whitehall-Robins' clinical trial in 234 subjects aged 65 or older indicates that the gastrointestinal safety profile of Advil is similar to placebo, according to results presented at the American College of Gastroenterology annual scientific meeting in Boston on Oct. 12. The subjects were a subset of a larger study involving 1,246 subjects comparing the GI safety profile of two Advil formulations: the new liqui-gel and a film-coated tablet. There were "no significant differences" between the treatment groups and placebo in terms of adverse events including dyspepsia, diarrhea, abdominal pain, nausea and intestinal ulceration, the study by Geraldine Doyle, PhD, et al. found
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel